Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA Enterprise value

Enterprise value at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$3.87B+95.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$6.74B+280%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$5.84B+181%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$12.92B+175%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.27B-4.1%

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.24B+128%
P/E58×—
P/S5.6×+1.8×

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

$3.7Bmarket cap+$9.0Mtotal debt−$190.0Mcash and equivalents=$3.5B

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's enterprise value?
Kiniksa Pharmaceuticals International, plc (KNSA) reported enterprise value of $3.5B in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's enterprise value changed year-over-year?
Kiniksa Pharmaceuticals International, plc's enterprise value increased by 139.0% year-over-year, from $1.47B to $3.5B.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's enterprise value?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's enterprise value has grown at a 21.8% compound annual growth rate (CAGR), from $1.11B to $2.97B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.